That eliminated my concern that the trial results may have somehow stopped further research. Good news and will keep Brilacidin in the forefront of future potential for fighting deadly viruses.
Leo also claimed B-COVID generated promising preclinical data (SI-426 anyone?), but failed spectacularly in clinical trial. What makes you think this time is any different?